Increased release of dopamine in vivo by BMY-14802: Contrasting pattern to clozapine

doi:10.1016/0028-3908(90)90173-O

Paper

DOI: 10.1016/0028-3908(90)90173-O

Increased release of dopamine in vivo by BMY-14802: Contrasting pattern to clozapine

Published May 1, 1990 · T. Rao, J. Cler, E. Oei

Neuropharmacology

Q1 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

BMY-14802 increases dopamine metabolism and release in vivo, suggesting its atyplcal profile is not solely due to its depressant actions on dopamine release.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1016/0304-3940(89)90512-0

Differences in dopamine release and metabolism in rat striatal subregions following acute clozapine using in vivo microdialysis

Acute clozapine administration increases dopamine release in the dorsolateral striatum but not in the fundus, highlighting the functional heterogeneity of the striatum.

1989·26citations·W. O’Connor et al.·Neuroscience Letters

Neuroscience Letters

DOI: 10.1111/j.1476-5381.1988.tb11605.x

Actions of dopamine antagonists on stimulated striatal and limbic dopamine release: an in vivo voltammetric study

Striatal and limbic dopamine release are controlled by a stereoselective dopamine D2 autoreceptor, with atypical neuroleptics showing no limbic-selective effect after acute administration.

1988·42citations·J. Stamford et al.·British Journal of Pharmacology

British Journal of Pharmacology

DOI: 10.1016/s0022-3565(25)24245-8

Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies.

BMY 14802 shows potential antipsychotic effects without significant extrapyramidal side effects by influencing dopamine neurotransmission through a nondopaminergic mechanism.

1988·69citations·S. Wachtel et al.·The Journal of pharmacology and experimental therapeutics

The Journal of pharmacology and experimental therapeutics

DOI: 10.1016/s0022-3565(25)23896-4

Effects of BMY 14802, a potential antipsychotic drug, on rat brain dopaminergic function.

BMY 14802-1 shows potential as a neuroleptic by blocking dopamine-mediated effects in the brain through a non-receptor mechanism.

1986·51citations·R. Matthews et al.·The Journal of pharmacology and experimental therapeutics

The Journal of pharmacology and experimental therapeutics

DOI: 10.1016/0278-5846(83)90062-3

Differential actions of classical and atypical neuroleptics on mouse nigrostriatal neurons

Atypical neuroleptics inhibit dopamine release, while classical neuroleptics increase dopamine metabolism and release, with sulpiride potentially not being an atypical agent.

1983·20citations·P. Wood et al.·Progress in Neuro-Psychopharmacology and Biological Psychiatry

Progress in Neuro-Psychopharmacology and Biological Psychiatry

DOI: 10.1002/BMS.1200090706

A selected ion monitoring assay for dopamine and its metabolites using negative chemical ionization.

Negative chemical ionization significantly increases sensitivity in measuring dopamine and its metabolites in biological samples.

1982·65citations·P. Wood·Biomedical mass spectrometry

Biomedical mass spectrometry

DOI: 10.1016/0024-3205(78)90105-4

3-Methoxytyramine and different neuroleptics: dissociation from HVA and DOPAC.

Haloperidol increases striatal 3-methoxytyramine levels, while clozapine does not, suggesting mechanisms in the substantia nigra play a role in modulating this effect.

1978·28citations·A. Groppetti et al.·Life sciences

Life sciences

DOI: 10.1002/DDR.430110109

Potential antipsychotic BMY 14802 selectively binds to sigma sites

BMY 14802 shows potential as an antipsychotic agent with fewer side effects than current drugs, and selectively inhibits binding at the s site, offering a new approach for developing new antipsychotic agents.

1987·126citations·Duncan P. Taylor et al.·Drug Development Research

Drug Development Research

Citations

DOI: 10.1016/S0014-2999(96)00699-1

5-HT1A receptor agonist effects of BMY-14802 on serotonin release in dorsal raphe and hippocampus.

BMY-14802 decreases serotonin release in the dorsal raphe and hippocampus by binding to 5-HT1A receptors, suggesting potential anxiolytic effects.

1996·11citations·F. Matos et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/0028-3908(92)90137-E

Lack of involvement of haloperidol-sensitive sigma binding sites in modulation of dopamine neuronal activity and induction of dystonias by antipsychotic drugs

Haloperidol-sensitive sigma binding sites do not play a role in modulating dopamine neuronal activity or inducing extrapyramidal motor dysfunction in antipsychotic drugs.

1992·13citations·L. Meltzer et al.·Neuropharmacology

Neuropharmacology

DOI: 10.1002/syn.890110402

Acute effects of Sigma ligands on the electrophysiological activity of rat nigrostriatal and mesoaccumbal dopaminergic neurons

Acute sigma receptor occupation does not significantly alter dopaminergic neuron firing rates, with some ligands showing marked effects due to their non-sigma properties.

1992·21citations·Jing Zhang et al.·Synapse

Synapse

DOI: 10.1016/0006-8993(92)90741-Q

Dopamine-, NMDA- and sigma-receptor antagonists exert differential effects on basal and amphetamine-induced changes in neostriatal ascorbate and DOPAC in awake, behaving rats

Dopamine, sigma, and NMDA receptor antagonists modulate neostriatal ascorbate release, but they have opposing effects on extracellular DOPAC, suggesting multiple mechanisms in amphetamine's behavioral effects.

1992·26citations·R. Christopher Pierce et al.·Brain Research

Brain Research

DOI: 10.1016/0028-3908(92)90026-L

Neuroendocrinological and neurochemical effects of sigma ligands

Sigma ligands, such as BMY 14802, tiospirone, remoxipride, and gevotriline, may be antipsychotic agents with an atypical profile of action, affecting prolactin, corticosterone secretion, and dop

1992·23citations·G. Gudelsky et al.·Neuropharmacology

Neuropharmacology